Cognitive Impairment After Critical Illness, Links Between Sepsis, Cognitive Function and Non-resolving Inflammation
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Is HMGB1 elevated in sepsis patients for weeks after recovery from severe sepsis/septic shock, similar to what has been observed in mice?
Study Overview
Brief Summary
Is HMGB1 (High Mobility Group Box 1) elevated in sepsis patients for weeks after recovery from severe sepsis/septic shock, similar to what has been observed in mice? Do patients recovering from severe sepsis/septic shock suffer from cognitive impairment and is such impairment associated with prolonged HMGB1 levels in plasma? Is there a difference from patients recovering from critical illness without prior sepsis?
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male/Female age 18-17
- •Expected ICU-stay more than 24 hours
Exclusion Criteria
- •Dont understand the language
- •Substance abuse, alcohol or drugs
- •Blind, deaf or suffering from aphasia
- •Ongoing psychiatric illness or psychopharmacological treatment
- •Suffering from dementia och mentally impaired
- •Structured brain damage or meningitis
- •Palliative Care
- •ICU-treated for more than 48 hours
- •Transferred from other ICU
- •Being treated with ECMO
- •Not having residency in Stockholm
Outcomes
Primary Outcomes
Is HMGB1 elevated in sepsis patients for weeks after recovery from severe sepsis/septic shock, similar to what has been observed in mice?
Time Frame: 2 years
Do patients recovering from severe sepsis/septic shock suffer from cognitive impairment and is such impairment associated with prolonged HMGB1 levels in plasma? Is there a difference from patients recovering from critical illness without prior sepsis?
Time Frame: 4 years
Secondary Outcomes
No secondary outcomes reported
Investigators
Peter Sackey
MD, PhD
Karolinska University Hospital